Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 10 selected

Guidance programme

Showing 51 to 100 of 571

TitleReference numberPublishedLast updated
Ranibizumab for treating diabetic macular oedemaTA274
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Stroke rehabilitation in adultsNG236
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Thyroid disease: assessment and managementNG145
Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritisTA918
Pegunigalsidase alfa for treating Fabry diseaseTA915
Bimekizumab for treating active psoriatic arthritisTA916
Urinary incontinence in neurological disease: assessment and managementCG148
Ovarian cancer: recognition and initial managementCG122
Suspected neurological conditions: recognition and referralNG127
Hearing loss in adults: assessment and managementNG98
Birch bark extract for treating epidermolysis bullosaHST28
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Cirrhosis in over 16s: assessment and managementNG50
Spinal metastases and metastatic spinal cord compressionNG234
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathyTA913
Semaglutide for managing overweight and obesityTA875
Otitis media with effusion in under 12sNG233
Ectopic pregnancy and miscarriage: diagnosis and initial managementNG126
Cipaglucosidase alfa with miglustat for treating late-onset Pompe diseaseTA912
Venous thromboembolic diseases: diagnosis, management and thrombophilia testingNG158
Afamelanotide for treating erythropoietic protoporphyriaHST27
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)TA910
Rimegepant for preventing migraineTA906
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapyTA908
Oesophago-gastric cancer: assessment and management in adultsNG83
Deucravacitinib for treating moderate to severe plaque psoriasisTA907
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA902
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancerTA903
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Upadacitinib for previously treated moderately to severely active Crohn's diseaseTA905
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Tixagevimab plus cilgavimab for preventing COVID-19TA900
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Bulevirtide for treating chronic hepatitis DTA896
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)TA899
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891

Results per page

  1. 10
  2. 25
  3. 50
  4. All